Thermo Fisher Scientific (NYSE:TMO) Stock Rating Upgraded by Wall Street Zen

Key Points

• Thermo Fisher Scientific was upgraded to a "buy" rating by Wall Street Zen, reflecting positive sentiment from several analysts regarding the stock's potential.
• The stock has a consensus rating of "Moderate Buy" with a price target averaging $593.00, supported by endorsements from 16 analysts with buy ratings.
• In its recent earnings report, Thermo Fisher reported $5.36 EPS, surpassing expectations and showing a revenue increase of 2.9% year-over-year.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday.

A number of other equities research analysts have also issued reports on TMO. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Barclays upped their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. UBS Group upped their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Raymond James Financial reaffirmed an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded up $3.31 during trading on Friday, hitting $493.05. 1,228,194 shares of the stock traded hands, compared to its average volume of 1,834,312. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The company has a market cap of $186.18 billion, a price-to-earnings ratio of 28.52, a P/E/G ratio of 2.63 and a beta of 0.75. The company has a fifty day moving average price of $454.36 and a two-hundred day moving average price of $453.50. Thermo Fisher Scientific has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts predict that Thermo Fisher Scientific will post 23.28 EPS for the current year.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 28,896 shares of company stock worth $13,603,438 over the last 90 days. Insiders own 0.33% of the company's stock.

Institutional Trading of Thermo Fisher Scientific

Large investors have recently made changes to their positions in the company. Mondrian Investment Partners LTD increased its stake in Thermo Fisher Scientific by 146.1% in the first quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock valued at $106,738,000 after purchasing an additional 127,357 shares during the last quarter. GAMMA Investing LLC increased its stake in Thermo Fisher Scientific by 22.0% in the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares during the last quarter. Deutsche Bank AG increased its stake in Thermo Fisher Scientific by 9.5% in the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after purchasing an additional 114,277 shares during the last quarter. Cetera Trust Company N.A increased its stake in Thermo Fisher Scientific by 3.3% in the first quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock valued at $2,312,000 after purchasing an additional 150 shares during the last quarter. Finally, Philip James Wealth Mangement LLC purchased a new position in Thermo Fisher Scientific in the first quarter valued at approximately $268,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.